Already the fourth most common cancer in women in the developed world, the incidence of endometrial cancer is increasing rapidly, in line with the rising prevalence of obesity. Relatively few studies have been undertaken of risk-reducing interventions aimed at limiting the impact of the disease on both individuals and the health service. Those that have been performed have demonstrated only modest results due to their application in relatively unselected populations. A validated risk prediction model is therefore urgently required to identify individuals at particularly high risk of endometrial cancer who may benefit from targeted primary prevention strategies and to guide trial eligibility. Based on a systematic review of the literature, the evidence for inclusion of measures of obesity, reproduction, insulin resistance and genetic risk in such a model is discussed, and the strength of association between these risk factors and endometrial cancer is used to guide the development of a pragmatic risk prediction scoring system that could be implemented in the general population. Provisional cut-off values are described pending refinement of the model and external validation in large prospective cohorts. Potential risk-reducing interventions are suggested, highlighting the need for future studies in this area if the rising tide of endometrial cancer is to be stemmed.
Introduction
Endometrial cancer is the fourth most common cancer in women in the UK, with over 9000 new diagnoses made in 2013 (1). The incidence is increasing not only in the developed world, where case numbers have more than doubled in the last 20 years, but is also expected to rise in lower income countries as the global burden of obesity worsens (2) . Given the current trajectory, it is predicted that by 2030 there will be an additional 3700 new cases of endometrial cancer diagnosed each year in the UK [ figure 1 ] (3, 4) . In line with this, mortality rates are also rising, albeit to a lesser extent, with a further 850 endometrial cancer deaths per year anticipated in England and Wales alone by 2030 (3) . Whilst endometrial cancer usually presents early, the morbidity associated with treatment, particularly in an increasingly elderly population, is not insignificant and disease recurrence, despite adjuvant treatment, continues to be a problem. Intervention is urgently required to stem this rising tide of endometrial cancer if the effects, both for individual patients and the health service, are not to become overwhelming.
Reducing the incidence of endometrial cancer requires the introduction of risk-reducing measures, used selectively in those at greatest disease risk and targeted at key mechanisms driving endometrial carcinogenesis. Previously studied interventions have often been found to have only a modest effect on disease risk, mainly due to their application in relatively unselected populations with the result that more pronounced benefits for specific subgroups may be diluted (table 1) . This highlights the importance of developing better risk prediction models to identify specific patient groups in whom these candidate risk-reducing interventions can be trialled to maximise their potential impact.
Here we propose a pragmatic risk prediction model to stratify the general female population into low, medium and high-risk groups for endometrioid endometrial cancer, the most common histological subtype [75% of all endometrial cancers] (5) and for which there is the greatest understanding of underlying risk factors and potential carcinogenic mechanisms. Given that the number of cases peaks when women are in their mid to late 60s, such a model would be aimed at women aged 45-55 years with an intact uterus, allowing sufficient time for any benefit from prophylaxis to be realised. Experimental and epidemiological evidence will be used to argue for the inclusion of measures of obesity (obesity score), unopposed oestrogen exposure (reproductive risk score), insulin resistance (insulin resistance risk score) and family history (genetic risk score) to identify individuals at greatest risk and will include protective factors which may negate these risks.
The rationale for using specific risk-reducing measures in subgroups based on their predominant endometrial cancer risk factor will also be explored.
There are two limitations to this approach, which must be appreciated at the outset. Whilst such a model is likely to have maximal impact on disease burden, it may not significantly reduce endometrial cancer mortality as non-endometrioid tumours are more biologically aggressive and associated with poorer prognosis. The second point is that it may fail to protect women with undiagnosed Lynch syndrome in whom endometrial cancer often presents at an earlier age (<45 years); however, the model is designed to target the general population rather than those at a particularly high genetic risk of the disease (6) .
Obesity score (O)
Any risk prediction model for endometrial cancer will be centred on measures of excess adiposity. It is estimated that up to 41% of endometrial cancer cases are directly attributable to women being overweight or obese and endometrial cancer has the strongest link with obesity of the 20 most common tumour types (6, 7) . Several underlying mechanisms linking excess adiposity and endometrial cancer have been described; excess oestrogen production, insulin resistance and inflammation (figure 2). Each is discussed further in the relevant sections.
Numerous measures of obesity exist, but the most commonly used, cheapest and easiest to apply in a clinic setting is body mass index (BMI), calculated using the formula weight (kg)/ height (m) 2 .
BMI
Meta-analyses of prospective observational studies have shown that a 5kg/m 2 increase in BMI is associated with a 60% increase in the relative risk of developing endometrial cancer (6, 8 (12) . Even those persistently obese women, benefit from a 50% lowering of endometrial cancer risk following surgery, suggesting that metabolic changes, such as improvements in insulin sensitivity, are also important in this context (12) . Additional health benefits associated with bariatric surgery include a reduction in the incidence of other obesity related cancers, including postmenopausal breast and colorectal cancer, as well as resolution of diabetes, hypertension, angina and obstructive sleep apnoea (13) . These benefits need to be incorporated into cost-effectiveness studies when determining the value of weight loss surgery in cancer prevention.
Focusing solely on women with the highest BMI (≥40kg/m 2 ), however, limits the benefits from endometrial cancer prevention to only 3% of the female population (14). Other measures of adiposity, such as central obesity and weight gain over time, can also be used to identify those women with lower BMIs who also have a particularly high risk of developing endometrial cancer.
Body fat distribution
Body fat distribution is potentially a better predictor of cancer risk for obesity associated malignancies than BMI, especially in breast cancer (15) . Measures which assess the extent of central vs. peripheral obesity can, therefore, be useful to further stratify patients within a particular BMI category. This can easily be performed using a ratio of waist to hip circumference; a value greater than 0.8 is consistent with central adiposity and an adverse metabolic phenotype, even in individuals with a normal body weight (16) .
Despite the findings in other cancer types, the endometrial cancer literature is divided as to whether there is an independent relationship between waist:hip ratio and endometrial cancer risk (17) (18) (19) .
Importantly, studies with the most discrepant results were undertaken in markedly dissimilar populations, with significantly different proportions of obese women. After adjusting for BMI, a meta-analysis of prospective observational studies found a non-significant increase in endometrial cancer risk with each 0.1-unit increase in waist:hip ratio [RR 1.07, 95% CI 0.97-1.17] (19).
Individually, however, both waist and hip circumference were independently associated with disease risk (RR 2.16 and 1.30 per 10cm increase in waist and hip circumference, respectively). These studies, however, were noted to be heterogeneous in design and frequently relied on self-reported measurements, which can be particularly difficult to perform in obese women where waist and hip landmarks are more problematic to identify. (17) .
Effect of weight change
Whilst current BMI has a significant influence on endometrial cancer risk, weight change over time is also important and is factored into the risk prediction model. This is based on results from the metaanalysis discussed above, in which an increase in weight between the ages of 18-20 years and middle age was associated with a higher endometrial cancer risk, even after adjusting for current BMI (19) .
For each 5kg increase in weight over this time period, the risk of endometrial cancer rose by 18% (95% CI 15-21%). Importantly, this result has been replicated in a non-Western population, with lower overall levels of obesity, and may be more pronounced in women with a higher starting BMI in their late teens/early twenties (20) . The caveat to the use of weight gain in a predictive model of endometrial cancer risk is its reliance on estimates of historical weight and the inaccuracies inherent to such data.
Adipokines
In addition to clinical measurements of body mass and adiposity distribution, adiponectin levels are also included as a serum biomarker of obesity and an adverse metabolic phenotype. Adiponectin is secreted by adipose tissue, though levels are inversely correlated with BMI (21). Biologically, it has an anti-cancer effect, acting as an anti-inflammatory and improving insulin sensitivity, whilst inhibiting angiogenesis and downregulating vascular adhesion molecule expression (22) . This is achieved through activation of AMPK and inactivation of ERK and MAPK (figure 2). It is also able to increase apoptosis by inducing expression of p53 and Bax, thereby acting as a negative regulator of tumour formation (23) . Higher serum levels of adiponectin are associated with a reduction in endometrial cancer risk (summary OR 0.47, 95% CI 0.34-0.65) with evidence of a dose-response relationship (24) . For each 5µg/ml increase in adiponectin levels, the risk of endometrial cancer has been found to decrease by 18%, an effect consistent across analyses adjusted for confounding factors, such as menopausal status, BMI and HRT use. This supports the distinction between metabolically healthy and metabolically unhealthy obese individuals and is incorporated into the risk prediction model as a protective factor (25) .
At present there is insufficient evidence to support the inclusion of the other important adipokine, leptin, in the risk model. It is also secreted by adipocytes and is involved in energy homeostasis, with levels increasing in proportion with body mass (26) . It has multiple cellular effects in vitro, any or all of which are associated with an increased risk of tumour formation, including proinflammatory, proangiogenic, mitogenic and anti-apoptotic effects, through activation of MAPK, PI3K and STAT pathways and increases in aromatase activity (26) . Whilst a meta-analysis of observational studies found that women with leptin levels in the upper tertile had a two-fold increase in their risk of endometrial cancer compared to those with the lowest levels, independent of BMI, the included studies were heterogeneous in design and inclusion criteria and insufficient data was available to determine whether a dose-response relationship existed.. Further work is, therefore, required to quantify the relationship between leptin levels and endometrial cancer risk before it can be included in any prediction model.
Each of the obesity measures discussed is derived from good quality epidemiological and in vitro evidence demonstrating a dose-response relationship between excess adiposity and endometrial cancer risk. Whilst they are included to measure different aspects of this association, in order to avoid 'double counting' obesity in the risk prediction model, the highest score of any of the clinical obesity measures added to the serum adiponectin score will be combined with the reproductive, insulin and genetic risk scores to derive the overall score.
Reproductive risk score (R)
Established reproductive risk factors for endometrial cancer can be interpreted in light of the 'unopposed oestrogen theory'. Oestrogen induces endometrial proliferation through local production of insulin-like growth factor-1 (IGF-1), increasing the risk of accumulation of genetic mutations in proto-oncogenes and tumour suppressor genes (27) . It is also responsible for an increase in free radical mediated DNA damage and inhibition of apoptosis (26, 27) . Increased lifetime exposure to oestrogen, through early menarche (<12 years) or late menopause (≥55 years) is, not surprisingly, associated with an increased risk of endometrial cancer (28) . Whilst oestrogen only HRT is a time-honoured risk factor for endometrial cancer, it is now so rarely used in women with an intact uterus that it has not been included in the risk prediction model. Conversely, use of the COCP for ≥ 5 years is associated with a significant reduction in endometrial cancer risk due to suppression of endogenous oestrogen levels and increased exposure to progesterone throughout the menstrual cycle (29) . For the same reason, increasing parity is a protective factor; a meta-analysis of 46 studies
showed that, compared with nulliparous women, women that had had one child had a 27% lower risk of developing endometrial cancer (RR 0.73 5%CI 0.64-0.84) and those with two children a 38% reduction in endometrial cancer risk (RR 0.62, 95%CI 0.53-0.74) (30). Whilst there was some evidence of a dose response relationship between parity and endometrial cancer risk, the numbers of included women with three or more children were too small to draw meaningful conclusions from.
For postmenopausal women, adipose tissue becomes the dominant source of oestrogen, responsible for the conversion of androstenedione and testosterone into oestrogen and oestradiol by aromatase and 17β-hydroxysteroid dehydrogenase (17β-HSD) produced by adipocytes (28, 31) . Obesity hence plays a significant role in postmenopausal oestrogen production and also increases its bioavailability by reducing sex hormone binding globulin production (figure 2).
Increased oestrogen levels are not seen in premenopausal women who develop endometrial cancer, however; instead a relative deficiency of progesterone appears to be important. Progesterone counteracts the mitogenic effects of oestrogen by increasing synthesis of insulin-like growth factor binding protein-1 (IGFPB-1) to mop up excess IGF-1 and promoting expression of the oestrogen sulfo-transferase and 17β-HSD enzymes, to convert oestradiol into the less potent oestrone (27) .
Women with prolonged periods of anovulation, such as those with polycystic ovary syndrome (PCOS), are not exposed to the protective effects of progesterone during the luteal phase of the menstrual cycle and are at heightened risk of endometrial cancer. In contrast, users of progesterone -releasing intrauterine systems (Mirena®) have a significantly lower risk of endometrial cancer compared with non-users [standardized incidence ratio 0.46, 95% CI 0.33-0.64] (32).
Tamoxifen, a selective oestrogen receptor modulator, is used to treat and less frequently prevent breast cancer, by inhibiting the growth of breast cancer cells. This is at the expense, however, of stimulating endometrial proliferation, resulting in a 2-3-fold increase in the risk of developing endometrial cancer for tamoxifen users (33, 34) . This effect appears to be restricted to postmenopausal women exposed to the drug. The risk of endometrial cancer increases with duration of exposure and dose used, though even low doses used for 2 years are associated with an increased risk of disease (35, 36) . This effect appears to persist even after its discontinuation. Ever use of tamoxifen, therefore, is included as a risk factor in the prediction model.
Previous risk prediction models incorporating these reproductive risk factors have produced varying results depending upon the population studied. When performed using the European Prospective
Investigation into Cancer and nutrition (EPIC) cohort of both pre and postmenopausal women, inclusion of these variables improved the discriminatory capability of the model over the use of age alone in predicting endometrial cancer, with an overall C-statistic of 77% (37) . In contrast, Pfeiffer, Park (38) found a significant over-prediction of endometrial cancer risk in their postmenopausal population using a similar model. The ability of our prediction model to accurately identify those at increased risk of endometrial cancer is enhanced through the inclusion of serum biomarkers of reproductive risk alongside these epidemiological risk factors (table 2) .
The decision to include androgen levels was based on data from large prospective nested casecontrol studies, which have shown that levels of total and, especially, free testosterone are increased in endometrial cancer cases compared with healthy controls (39) . Whilst there is insufficient data available in the literature to determine optimal cut-off values, free testosterone levels of > 17pmol/l appear to be associated with the development of endometrial cancer in both pre-and postmenopausal women (39, 40) . This effect is independent of BMI and precedes a diagnosis of endometrial cancer (by a median of 11.2 years), allowing adequate time for prophylactic intervention to be instituted. Measurement of serum free androgens also has the advantage that levels are unaffected by the menstrual cycle, avoiding the complexities of timing blood sampling that is seen with other sex hormones. It is as yet unclear whether elevated androgen levels are associated with an increased risk of developing pre-menopausal endometrial cancer as the study by Clendenen, Hertzmark (40) found no association if a diagnosis was made prior to the age of 55 years, though their analysis was based on only 49 cases and 86 controls. The molecular effect of testosterone on the endometrium and endometrial cancer cells is still debated, but it would appear logical for it to be included in the prediction model, given the close association between elevated androgen levels, obesity and oestrogen production in postmenopausal women and PCOS in younger individuals (40) .
Measurement of serum oestrogen levels was discounted from the model on the basis that it was only of value in determining endometrial cancer risk in postmenopausal women. Several casecontrol and prospective cohort studies have found increased levels of endogenous total and free oestrogen in postmenopausal women with endometrial cancer compared with controls, with oestradiol levels in the upper tertile being associated with a 2-4 fold increase in endometrial cancer risk (27, 41, 42) . In premenopausal women, however, this relationship is not evident, limiting its applicability in our target population (43) . There are no published studies evaluating progesterone as a marker of endometrial cancer risk, though as levels vary dramatically throughout the menstrual cycle, attempting to control for this would be difficult (27) .
Insulin risk score (I)
The third component of the risk prediction model, and an area receiving increasing attention, is the effect of insulin resistance on the development of endometrial cancer. There is now substantial in vitro evidence for a direct effect of insulin and IGF-1 on endometrial cancer cells, with activation of the insulin receptor resulting in an increase in cell proliferation and inhibition of apoptosis (44, 45) .
These effects are mediated through both the MAPK and PI3K/Akt pathways (figure 2). Insulin and IGF-1 also stimulate β-catenin, a signalling pathway involved in early tumour formation, and through this the oncogene Ras. By increasing the breakdown of IGFBP-3, insulin is able to act to increase levels of free IGF-1 and thus enhance its tumour promoting capacity. Beyond these direct effects, hyperinsulinemia is also involved in increasing ovarian androgen production and peripheral aromatisation to oestrogen, reducing sex hormone binding globulin and adiponectin levels and stimulating leptin secretion, highlighting the interdependence of these mechanisms (44) .
In line with this, a diagnosis of type 2 diabetes mellitus is included in the model as its presence is associated with a greater than two fold elevation in endometrial cancer risk, even after adjustment for activity levels and BMI (46) . Similarly, PCOS, whilst featuring in the reproductive risk score because of its link with hyper-androgenaemia, is also included in the insulin risk score; 50-70% of patients with PCOS are also insulin resistant and this group have a particularly high endometrial cancer risk (47) . Despite the epidemiological evidence supporting an increased risk of endometrial cancer for those with elevated insulin levels, large scale testing is not possible due to the lack of a standardised protocol for sample preparation and testing and the absence of validated cut-off values to stratify patients into high and low risk groups (48) (49) (50) (51) . For these reasons surrogate measures of insulin sensitivity, such as HOMA-IR and QUICKI, which rely on accurate insulin level measurements, have also not been included. The gold-standard test of insulin sensitivity is the euglycaemic clamp test, but this is too expensive and time-consuming to be used apart from on an individual patient basis (52) . Whilst measurement of IGF-1 levels would circumvent many of these problems, no consistent association between serum IGF-1 and endometrial cancer risk has been demonstrated, suggesting that local endometrial IGF-1 production may be more relevant than systemic levels (51).
On the basis of current evidence and with mind to the practicalities of screening a large number of patients, we propose incorporating the pro-insulin protein, C-peptide, into a risk prediction model. It is stored intracellularly with insulin and the two are released together in equal amounts; higher levels of C-peptide thus reflect increased endogenous insulin secretion and insulin resistance. It has the advantage of having a longer half-life than insulin and more accurately reflects insulin levels if there is variation in fasting time. An absolute requirement for fasting samples is also not necessary.
Five observational studies have been conducted examining the relationship between C-peptide levels and endometrial cancer, the results of which were combined in a meta-analysis (49) . Both fasting and non-fasting levels were significantly higher in patients who subsequently developed endometrial cancer compared with controls, with evidence of a dose-response relationship (51, 53) .
Only one study reported on actual C-peptide levels rather than study specific quintiles; a level greater than 0.76nmol/l is associated with 1.5-2 fold elevation in endometrial cancer risk and is used in the model (53 
Genetic risk score (G)
The risk of endometrial cancer in women with Lynch syndrome (mutations in the DNA mismatch repair genes MSH2, 6, MLH1, PMS2 or EPCAM) is significantly elevated, with a cumulative risk of endometrial cancer of 16-71% by the age of 70 years, depending upon the specific gene affected (55, 56) . Despite this, the role of screening for endometrial cancer in women with Lynch syndrome and the value of prophylactic intervention to reduce this risk have yet to be clearly defined and is the subject of ongoing research. As this model has been developed for use in the general population, this topic will not be discussed further here. history of colorectal cancer is much lower and overall not significantly higher than for women without a family history. Whilst both inherited mutations in genes critical to endometrial carcinogenesis and the presence of shared risk factors (including obesity) for the condition may explain this association, the exact mechanisms have yet to be determined.
Inflammation
Whilst not directly incorporated at present, future work may well see measures of inflammation feature in the risk prediction model. Adipose tissue is increasingly being recognised as playing an active role in many diseases, including cancer, through the release of adipokines, cytokines and sex hormone metabolism (58) .Obesity is, itself, a state characterised by chronic inflammation (59). Women's Health Initiative cohorts found higher levels of inflammatory mediators to precede a diagnosis of endometrial cancer, though the association was largely dependent on the degree of adiposity (61, 63) . There is, however, some debate about which cytokines are specifically elevated in endometrial cancer and the optimal laboratory technique for their measurement. In particular, these proteins may be too non-specific to be used in a risk prediction model; levels are elevated transiently in numerous situations, including sub-clinical infection. Longitudinal, prospective cohort studies are required to evaluate the role of inflammatory cytokines, such as IL-6 and CRP, in endometrial cancer risk stratification and to determine whether repeated measures over time are of greater predictive value than one-off measurements. Should this evidence be forthcoming, it would support the targeted use of aspirin as a prophylactic intervention for those with an increased inflammation risk score. This has already been shown to be the case for women with Lynch syndrome in the CAPP2 study, where treatment with aspirin for ≥2 years was associated with a 53% reduction in the incidence of endometrial cancer, although the mechanism underpinning this effect may well be different (64) .
Using the risk prediction model to target prophylaxis
The four individual components of the risk prediction model, genetic (G), insulin (I), reproductive (R) and obesity (O) scores, are combined to give an overall assessment of endometrial cancer risk, stratified into low, medium and high risk groups (table 2, figure 3 ). Based on an absolute lifetime risk of the disease of 2.4%, this approximates to an absolute risk of endometrial cancer of up to 4.9%, 7.3-17.1% and ≥ 19.5% for the low, medium and high risk groups, respectively (65). The predominant risk factor identified can be used to determine the type of prophylactic intervention trialled, for example, metformin when the insulin score is particularly high, the combined oral contraceptive pill or levonorgestrel-releasing intrauterine device if the reproductive score predominates.
The 'optimal' model for risk prediction will include all the clinical and serum biomarkers incorporated into Those within the high risk category require multimodal intervention to reduce their endometrial cancer risk, including diet and exercise advice, aspirin, metformin and a Mirena coil. For women with a BMI ≥40 and other endometrial cancer risk factors (particularly diabetes), bariatric surgery should also be offered; such a procedure would not only provide endometrial protection but also be associated with significant reductions in weight and improvements in insulin resistance.
Reassessment of endometrial cancer risk using the prediction model is likely to be required every five years. This allows the Mirena coil to be replaced, if necessary, to ensure continuing efficacy and change or introduce other prophylactic treatments depending upon an individual's risk score. Such assessments will continue until age 70, at which point the number of cases of the disease naturally declines and evidence for the validity of the components of the risk prediction model and prophylactic treatments discussed becomes more circumspect.
Conclusion
Mechanistic and epidemiological studies have provided useful information on which to guide the development of a prediction model for endometrial cancer risk. We propose that such a model should include measures of obesity, reproductive hormones, insulin resistance and family history, reflecting the interconnection of these mechanisms in driving endometrial cancer development. As it stands, this model is purely theoretical and requires formal testing in a large prospective cohort of asymptomatic women for whom long term outcome data is available. This will allow the model to be refined, using random decision forests and unconditional logistic regression, in order to optimise the weighting of included variables and ensure its accuracy in identifying individuals at high and low risk of the disease. Once calibrated, we propose to validate the model in a second, independent cohort, thereby verifying its applicability to the general population. The UK Biobank, with its recruitment of over 250,000 women and inclusion of anthropometric, biochemical and clinical follow-up data, will provide the ideal resource in which to conduct this work (66). With periodic release of information, the Biobank is a not-for-profit organisation established to assist researchers in understanding disease specific risk factors and the development of such prediction models. This information would not only allow the identification of individuals with a particularly high risk of developing endometrial cancer, but would also potentially guide the development of prophylactic treatment aimed at specific disease causing targets, such as insulin resistance and inflammation. Table 2 . Proposed endometrial cancer risk prediction model. Points are assigned as described for each individual risk factor. The highest single clinical obesity score is then added to the serum adiponectin score to give the final obesity score. This is combined with the total reproductive, insulin and genetic scores to give an overall total, which is used to assign patients into risk categories; 0-2 low risk, 3-7 medium risk, ≥8 high risk. Genetic, insulin, reproductive and obesity scores are combined and used to triage patients into low, medium and high risk groups. Women in the low risk category are offered diet and exercise advice and their risk score repeated in 5 years, whilst those in the medium risk group are offered prophylactic intervention in the form of aspirin and a Mirena coil or metformin, depending upon whether the reproductive risk or insulin risk score is higher, respectively. Women in the highest risk group are offered aspirin, Mirena and metformin prophylaxis and are referred for bariatric surgery, if appropriate.
